Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDS.

Barreau S, Green AS, Dussiau C, Alary AS, Raimbault A, Mathis S, Willems L, Bouscary D, Kosmider O, Bardet V, Fontenay M, Chapuis N.

Cytometry B Clin Cytom. 2019 Sep 9. doi: 10.1002/cyto.b.21843. [Epub ahead of print]

PMID:
31498561
2.

The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.

Raimbault A, Itzykson R, Willems L, Rousseau A, Chapuis N, Mathis S, Clauser S, Radford-Weiss I, Bouscary D, Fontenay M, Kosmider O, Bardet V.

Cytometry B Clin Cytom. 2019 May;96(3):215-222. doi: 10.1002/cyto.b.21781. Epub 2019 Apr 9.

PMID:
30963682
3.

Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report.

Sourdeau É, Clauser S, Prud'Homme R, Bardet V, Calmette L.

Ann Biol Clin (Paris). 2019 Apr 1;77(2):179-183. doi: 10.1684/abc.2018.1405.

PMID:
30882350
4.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2019 Mar;104(3):497-504. doi: 10.3324/haematol.2018.203158. Epub 2018 Oct 4.

5.

CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.

Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, Lauf J, Alary AS, Burroni B, Kosmider O, Fontenay M, Béné MC, Durrieu F, Bettelheim P, Bardet V.

Br J Haematol. 2019 Feb;184(4):625-633. doi: 10.1111/bjh.15584. Epub 2018 Sep 10.

PMID:
30198568
6.

A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice.

Schillinger F, Sourdeau E, Boubaya M, Baseggio L, Clauser S, Cornet E, Debord C, Defour JP, Dubois F, Eveillard M, Galoisy AC, Geay MO, Mullier F, Nivaggioni V, Soenen V, Morel P, Garnache-Ottou F, Ronez E, Bardet V, Deconinck E.

Scand J Clin Lab Invest. 2018 May;78(3):159-164. doi: 10.1080/00365513.2018.1423702. Epub 2018 Jan 8.

PMID:
29310473
7.

Harmonisation of full blood count reports, recommendations of the French-speaking cellular haematology group (GFHC).

Trimoreau F, Galoisy AC, Geneviève F, Bardet V, Cornet E, Hurst JP, Lesesve JF, Leymarie V, Lusina D, Perez B, Cahn JY, Damaj G, Ugo V, Troussard X; French-Speaking Cellular Haematology Group.

J Clin Pathol. 2017 May;70(5):395-402. doi: 10.1136/jclinpath-2016-204001. Epub 2016 Oct 11.

PMID:
27729428
8.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

9.

Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line.

Chenevier-Gobeaux C, Bardet V, Poupet H, Poyart C, Borderie D, Claessens YE.

Ann Biol Clin (Paris). 2016 Jan-Feb;74(1):93-7. doi: 10.1684/abc.2015.1112.

10.

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.

Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, Morabito M, Met E, Debord C, Benayoun E, Nloga AM, Fenaux P, Braun T, Willekens C, Quesnel B, Adès L, Fontenay M, Rameau P, Droin N, Koscielny S, Solary E; Francophone Myelodysplasia Group.

Blood. 2015 Jun 4;125(23):3618-26. doi: 10.1182/blood-2015-01-620781. Epub 2015 Apr 7.

11.

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Bardet V, Wagner-Ballon O, Guy J, Morvan C, Debord C, Trimoreau F, Benayoun E, Chapuis N, Freynet N, Rossi C, Mathis S, Gourin MP, Toma A, Béné MC, Feuillard J, Guérin E; Groupe Francophone des Myélodysplasies (GFM); Groupe d’Etude Immunologique des Leucémies (GEIL).

Haematologica. 2015 Apr;100(4):472-8. doi: 10.3324/haematol.2014.112755. Epub 2015 Jan 30.

12.

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.

Mathis S, Chapuis N, Borgeot J, Maynadié M, Fontenay M, Béné MC, Guy J, Bardet V.

Cytometry B Clin Cytom. 2015 Mar;88(2):101-9. doi: 10.1002/cyto.b.21200. Epub 2014 Nov 17.

13.

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F.

Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7.

14.

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.

Mathis S, Chapuis N, Borgeot J, Maynadié M, Fontenay M, Béné MC, Guy J, Bardet V.

Cytometry B Clin Cytom. 2014 Oct 28. doi: 10.1002/cytob.21200. [Epub ahead of print]

15.

[Determination of full blood count normal reference values for adults in France].

Troussard X, Vol S, Cornet E, Bardet V, Couaillac JP, Fossat C, Luce JC, Maldonado E, Siguret V, Tichet J, Lantieri O, Corberand J; Groupe francophone d'hématologie cellulaire (GFHC).

Ann Biol Clin (Paris). 2014 Sep-Oct;72(5):561-81. doi: 10.1684/abc.2014.0979. French.

16.

Schistocytes in disseminated intravascular coagulation.

Lesesve JF, Martin M, Banasiak C, André-Kerneïs E, Bardet V, Lusina D, Kharbach A, Geneviève F, Lecompte T.

Int J Lab Hematol. 2014 Aug;36(4):439-43. doi: 10.1111/ijlh.12168. Epub 2013 Nov 22.

PMID:
24261329
17.

Full blood count normal reference values for adults in France.

Troussard X, Vol S, Cornet E, Bardet V, Couaillac JP, Fossat C, Luce JC, Maldonado E, Siguret V, Tichet J, Lantieri O, Corberand J; French-Speaking Cellular Hematology Group (Groupe Francophone d'Hématologie Cellulaire, GFHC).

J Clin Pathol. 2014 Apr;67(4):341-4. doi: 10.1136/jclinpath-2013-201687. Epub 2013 Oct 29.

PMID:
24170208
18.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6.

19.

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.

Mathis S, Chapuis N, Debord C, Rouquette A, Radford-Weiss I, Park S, Dreyfus F, Lacombe C, Béné MC, Kosmider O, Fontenay M, Bardet V.

Leukemia. 2013 Oct;27(10):1981-7. doi: 10.1038/leu.2013.178. Epub 2013 Jun 14.

PMID:
23765225
20.

Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.

Kosmider O, Chapuis N, Kaltenbach S, Coriat R, Boudou Rouquette P, Willems L, Chesnais V, Radford-Weiss I, Bardet V, Mayeux P, Tamburini J, Fontenay M, Bouscary D.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):347-50. doi: 10.1016/j.clml.2012.11.007. No abstract available.

PMID:
23246161
21.

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.

Ettou S, Audureau E, Humbrecht C, Benet B, Jammes H, Clozel T, Bardet V, Lacombe C, Dreyfus F, Mayeux P, Solary E, Fontenay M.

Leukemia. 2012 Oct;26(10):2297-9. doi: 10.1038/leu.2012.152. Epub 2012 Jun 5. No abstract available.

PMID:
22743624
22.

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V.

Haematologica. 2011 Dec;96(12):1792-8. doi: 10.3324/haematol.2011.047894. Epub 2011 Sep 20.

23.

Leukemic phase of follicular lymphomas: an atypical presentation.

Al-Nawakil C, Kosmider O, Stern MH, Manié E, Bardet V, Leblond V, Park S, Dreyfus F, Bouscary D, Tamburini J.

Leuk Lymphoma. 2011 Aug;52(8):1504-8. doi: 10.3109/10428194.2011.574753. Epub 2011 May 17.

PMID:
21585282
24.

A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.

Frébet E, Abraham J, Geneviève F, Lepelley P, Daliphard S, Bardet V, Amsellem S, Guy J, Mullier F, Durrieu F, Venon MD, Leleu X, Jaccard A, Faucher JL, Béné MC, Feuillard J; GEIL Groupe d'Etude Immunologique des Leucémies Study Group.

Cytometry B Clin Cytom. 2011 May;80(3):176-85. doi: 10.1002/cyto.b.20581. Epub 2010 Dec 10.

25.

Evaluation of peroxidase activity by alpha-naphthol/pyronine staining compared with benzidine staining in 101 acute leukemia cases.

Latger-Cannard V, Bardet V, Malet M, Lagrange M, Empereur F, Fenneteau O.

Lab Hematol. 2010 Dec;16(4):76-82. doi: 10.1532/LH96.10007.

PMID:
21097443
26.

Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010.

Faure GC, Amsellem S, Arnoulet C, Bardet V, Campos L, De Carvalho-Bittencourt M, de Labarthe A, Eischen A, Feuillard J, Fossat C, Ottou FG, Guérin E, Guy J, Jouault H, Kuhlein E, Lacombe F, Lainey E, Maynadié M, Noguera ME, Roussel M, Solly F, Ballon OW, Béné MC; GEIL workshop.

Immunol Lett. 2011 Jan 30;134(2):145-9. doi: 10.1016/j.imlet.2010.10.008. Epub 2010 Oct 15.

PMID:
20951742
27.

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.

Clin Cancer Res. 2010 Nov 15;16(22):5424-35. doi: 10.1158/1078-0432.CCR-10-1102. Epub 2010 Sep 30.

28.

Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide.

Park S, Vassilieff D, Bardet V, Viguié F, Dreyfus F.

Leukemia. 2010 Nov;24(11):1960-2. doi: 10.1038/leu.2010.183. Epub 2010 Aug 19. No abstract available.

PMID:
20724986
29.

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.

Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D.

Leukemia. 2010 Oct;24(10):1686-99. doi: 10.1038/leu.2010.170. Epub 2010 Aug 12. Review.

PMID:
20703258
30.

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.

Chapuis N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Willems L, Agou F, Ifrah N, Dreyfus F, Bismuth G, Baud V, Lacombe C, Mayeux P, Bouscary D.

Blood. 2010 Nov 18;116(20):4240-50. doi: 10.1182/blood-2009-12-260711. Epub 2010 Jul 29.

31.

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.

Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, Hermine O, Moura IC, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Blood. 2010 Nov 18;116(20):4262-73. doi: 10.1182/blood-2010-02-269837. Epub 2010 Jul 28.

32.

Diagnostic and therapeutic considerations on inherited platelet disorders in neonates and children.

Schlegel N, Bardet V, Kenet G, Muntean W, Zieger B, Nowak-Göttl U; Working Group on Standardisation in Perinatal and Pediatric Hemostasis.

Klin Padiatr. 2010 May;222(3):209-14. doi: 10.1055/s-0030-1249065. Epub 2010 Jun 9.

PMID:
20535670
33.

Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage.

Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, Duménil D.

Blood. 2010 Apr 8;115(14):2784-95. doi: 10.1182/blood-2009-09-241752. Epub 2010 Feb 2.

34.

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Haematologica. 2010 Mar;95(3):415-23. doi: 10.3324/haematol.2009.010785. Epub 2009 Dec 8.

35.

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D.

Haematologica. 2010 May;95(5):819-28. doi: 10.3324/haematol.2009.013797. Epub 2009 Nov 30. Review.

36.

Targeting translation in acute myeloid leukemia: a new paradigm for therapy?

Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P, Bouscary D.

Cell Cycle. 2009 Dec;8(23):3893-9. Review.

PMID:
19934662
37.

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D.

Blood. 2009 Aug 20;114(8):1618-27. doi: 10.1182/blood-2008-10-184515. Epub 2009 May 20.

38.

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.

Al-Nawakil C, Tamburini J, Bardet V, Chapuis N, Bourry E, Roux C, Park S, Choquet S, Dreyfus F, Bouscary D.

Leuk Lymphoma. 2008 Oct;49(10):2012-4. doi: 10.1080/10428190802290660. No abstract available.

PMID:
18720213
39.

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Leukemia. 2008 Sep;22(9):1698-706. doi: 10.1038/leu.2008.144. Epub 2008 Jun 12.

PMID:
18548104
40.

A critical role for Lyn in acute myeloid leukemia.

Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Récher C.

Blood. 2008 Feb 15;111(4):2269-79. Epub 2007 Dec 3.

41.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F; GFM group (Groupe Francophone des Myélodysplasies).

Blood. 2008 Jan 15;111(2):574-82. Epub 2007 Oct 16.

42.

Images in haematology. Bilateral adrenal chloromas.

Sujobert P, Bardet V, Bienvenu M.

Br J Haematol. 2008 Feb;140(3):254. Epub 2007 Sep 25. No abstract available.

PMID:
17894842
43.

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Blood. 2008 Jan 1;111(1):379-82. Epub 2007 Sep 18.

44.

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Blood. 2007 Aug 1;110(3):1025-8. Epub 2007 Apr 10.

45.

Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.

Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F.

Liver Transpl. 2006 Nov;12(11):1649-54.

46.

[The MYH9 syndrome: report of a new case with a new mutation of the MYH9 gene].

Schleinitz N, Favier R, Mazodier K, Difeo A, Ebbo M, Veit V, Berda-Haddad Y, Bernit E, Heudier P, Kaplanski G, Camoin L, Bardet V, Harle JR.

Rev Med Interne. 2006 Oct;27(10):783-6. Epub 2006 Aug 15. French.

PMID:
16978745
47.

Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype.

Bardet V, Costa LD, Elie C, Malinge S, Demur C, Tamburini J, Lefebvre PC, Witz F, Lioure B, Jourdan E, Pigneux A, Ifrah N, Attal M, Dreyfus F, Mayeux P, Lacombe C, Bennaceur-Griscelli A, Bernard OA, Bouscary D, Récher C; GOELAMS: Groupe Ouest Est d'etude des Leucémies et des Autres Maladies du Sang.

Leukemia. 2006 Sep;20(9):1644-6. Epub 2006 Jun 22. No abstract available.

PMID:
16791266
48.

Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry.

Bardet V, Tamburini J, Ifrah N, Dreyfus F, Mayeux P, Bouscary D, Lacombe C.

Haematologica. 2006 Jun;91(6):757-64.

49.

Hb Calais [beta76(E20)Ala --> Pro]: a family study of a variant with decreased oxygen affinity.

Bardet V, Adam M, Yvart J, Wajcman H, Galacteros F, Favier R.

Hemoglobin. 2006;30(1):35-8.

PMID:
16540413
50.

Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations.

Cornillet-Lefebvre P, Cuccuini W, Bardet V, Tamburini J, Gillot L, Ifrah N, Nguyen P, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Leukemia. 2006 Feb;20(2):374-6. No abstract available.

PMID:
16341041

Supplemental Content

Loading ...
Support Center